According to latest research by Fact.MR, heparin market will witness substantial growth during the study period of 2021-2031.Demand for heparin market will elevate in the course of forecast period while experiencing a steady growth. Adverse effects caused by heparin such as heparin-induced thrombocytopenia is likely to have negative impact, However, Commercialization of cost-effective and safe products, with greater efficacy and lesser side effects is expected to offer new business opportunities.
What is Driving Demand for Heparin?
Heparin is widely used injectable anti-coagulant, which prevents the formation of blood clots. It has its application in pulmonary embolism, deep vein thrombosis, and other cardiovascular surgeries. High incidence of these disorders will augment the market growth. Also, increasing number of accident cases resulting in surgeries is expected to drive the growth of heparin market across the globe. As per Association for Safe International Travel, in 2020, approximately 4.4 million individuals were severely injured and require immediate medical attention in the U.S. alone. This high number injuries will lead to rise in demand of anti-coagulant agents such as heparin.
Additionally, growing research and development activities, FDA approvals and new product launch, promising clinical trial pipeline, introduction of novel products will lead to the significant growth in the forecast period.
Know More Details About the Report
New product developments Likely to Augment the Heparin Sales
Needle stick injuries is one of the common hazard in hospitals, and other clinical settings, which can lead to transmission and infection of various diseases. In order to overcome this issue, various leading players are focusing on introducing ready –to administer heparin in pre-filled syringes or IV bags.
In this regard, Fresenius Kabi, in April 2021 has introduced low concentration of Heparin Sodium Injection in Ready-to-use Freeflex Bags. Its Leak resistant technology, easy handling, and patient safety are some of the benefits associated with these bags. Such benefits are expected to drive its demand among hospitals, specialty clinics, ambulatory surgical centers which are the major end users of this products.
US and Canada Carbon Fiber Market Outlook
U.S. and Canada are among the largest market for heparin making North America a dominant player. According to the Centers of Disease Control and Prevention, an estimated 90,000 patients are affected by DVT/PE in the United States, Also, around 60,000-100,000 thousand Americans die of DVT/PE. Also, high incidence of thrombosis is recorded in the Canada. According to Thrombosis Canada, it is estimated that approximately 45,000 patients in Canada are affected by DVT each year, with incidence of 1-2 cases per 1,000 person annually.
Such high incidence of DVT/PE will augment the sales of heparin, thus having the positive impetus on the heparin market in these region.
Avail customized purchase options for your needs
Europe Demand Outlook for Heparin
Pulmonary Embolism (PE) following deep vein thrombosis affects 500,000 patients annually in the European region, which is one of the key factor attributed to the demand of the heparin. Apart from this, European market is marked by the presence of various leading manufactures such as Leo Pharma A/S, Aspen Holdings, B. Braun Melsungen AG, and Teva Pharmaceuticals Industries. The increase in production of heparin in major European Countries has Dirven the market substantially. Also, growing region specific research and developments, with focus on the improving mechanism of heparin will further aid the market growth.
Despite the positive outlook in this region, the availability and use of the other alternative anti-coagulants such as heparin such as warfarin is expected to hamper the sales of heparins in this region
Who are the Key Manufacturers and Suppliers of Heparin?
Some of the leading manufacturers and suppliers of heparin are
- Aspen Holdings
- Pfizer Inc.
- Leo pharma A/S
- B. Braun Melsungen AG
- Fresenius SE & Co
- N.V., Sandoz (Novartis AG)
- Hikma Pharmaceuticals PLC,
- Bioiberica S.A.U.
These manufactures aim to introduce the new products which with improved safety, and accuracy of the medicines. For instance, in September 2019, Hikma Pharmaceuticals introduced Heparin Sodium prefilled syringes, USP 5000 Units/ml. Also, in April 2019, another industry major, B. Braun introduced First FDA –approved Heparin sodium pre-filled syringes. Availability of such ready to administer products will help he healthcare provider to treat patients faster, with reduced risk of needle stick injuries.
An Adaptive Approach to Modern-day Research Needs
Heparin Market Report Highlights:
- Shifting Industry dynamics
- In-depth market segmentation
- Historical, current and projected industry size recent industry trends
- Key Competition landscape
- Strategies for key players and product offerings
- Potential and niche segments/regions exhibiting promising growth
- A neutral perspective towards market performance
NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of the company
Have a report related query? Speak to us directly
- Low molecular Weight Heparin (LMWH)
- Ultra-Low molecular weight heparin (ULMWH)
- Unfractionated Heparin
By Route of Administration
By Route of Application
- Venous Thromboembolism
- Pulmonary Embolism
- Cardiovascular disorders
- Renal Impairment
By End Users
- Specialty Clinics
- Ambulatory Surgical Centers (ASCs)
- North America
- Latin America
- Rest of Latin America
- Rest of Latin America
- East Asia
- South Korea
- South Asia
- Rest of South Asia
- New Zealand
- Middle East and Africa
- GCC Countries
- North Africa
- South Africa
- Rest of Middle East
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Need an Exclusive Report for your Unique Requirement?
- Our Clients -
- Evaluate How Fact.MR's Report Can Help. -
Is the market research conducted by Fact.MR?
Yes, the report on the radiation proctitis treatment industry has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Fact.MR?
Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.
What are the sources of secondary research?
Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Who are the respondents for primary research?
Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.